Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 1/20 | 0.67 |
| ▸ | F3 | P13726 | 1/20 | 0.67 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.67 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.67 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.67 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.67 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.67 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.67 |
| ▸ | SIRT4 | Q9Y6E7 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 4/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | APP | P05067 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.50 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mandelic Acid SCHEMBL810372 | 0.88 | ALDH1A1 (0.68) | F7F3SARM1SIRT2SIRT6 | |
| Cadaverine Tartrate SCHEMBL27679158 | 0.84 | F7 (0.76) | F7F3SARM1SIRT2SIRT6 | |
| Cadaverine Tartrate SCHEMBL29103712 | 0.84 | F7 (0.76) | F7F3SARM1SIRT2SIRT6 | |
| Benzamide SCHEMBL594793 | 0.84 | F7 (0.88) | F7F3SARM1SIRT2SIRT6 | |
| Niacinamide SCHEMBL675207 | 0.83 | F7 (0.96) | F7F3SARM1SIRT2SIRT6 | |
| Niacinamide SCHEMBL6698484 | 0.83 | F7 (0.73) | F7F3SARM1SIRT2SIRT6 | |
| Niacinamide SCHEMBL74569 | 0.83 | F7 (0.73) | F7F3SARM1SIRT2SIRT6 | |
| Niacinamide SCHEMBL460466 | 0.82 | F7 (1.00) | F7F3SARM1SIRT2SIRT6 | |
| Niacinamide SCHEMBL29624874 | 0.82 | — | — | |
| Niacinamide SCHEMBL2926 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060147508-A1 | Concurrent Enhancement of Skin Penetration of Organic Base Active Agents and Organic Hydroxy Acid Active Agents as Their Ion-Pair Complexes | BIODERM RESEARCH (US) | 2006-07-06 | — | — | US | claimed |
| US-20040228884-A1 | Ion-pair delivery system for cosmetic and pharmaceutical compositions | GUPTA SHYAM K (US) | 2004-11-18 | — | — | US | claimed |
| US-20040156873-A1 | Topically Bioavailable Acne and Rosacea Treatment Compositions | GUPTA SHYAM K (US) | 2004-08-12 | — | — | US | claimed |
| US-20040092482-A1 | Hydroxy acids based delivery systems for skin resurfacing and anti-aging compositions | GUPTA SHYAM K (US) | 2004-05-13 | — | — | US | claimed |
| CN-118302145-A | Cosmetic water-in-oil emulsion comprising a specific water-soluble UV screening agent, a base, a volatile oil, a hydrophobic film-forming polymer, a polyoxyalkylene-alkylated linear polydimethylsiloxane and vitamin B3 | 莱雅公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-117355289-A | Non-therapeutic cosmetic method for reducing wrinkles on the surface of the skin | 莱雅公司 | 2024-01-05 | — | — | CN | disclosed |
| CN-109641814-B | Non-corrosive nitration inhibitor polar solvent preparation | 美国陶氏益农公司 | 2021-12-31 | — | — | CN | disclosed |
| US-20180177703-A1 | Niacinamide Mononucleotide Formulations For Skin Aging | N.V. PERRICONE LLC | 2018-06-28 | — | — | US | disclosed |
| US-9987217-B2 | Blackberry extract | SYMRISE AG (DE) | 2018-06-05 | — | — | US | disclosed |
| WO-2016210232-A1 | NIACINAMIDE MONONUCLEOTIDE FORMULATIONS FOR SKIN AGING | N.V. PERRICONE LLC (US) | 2016-12-29 | — | — | WO | disclosed |
| US-20160220536-A1 | USE OF PHENYLMETHIMAZOLES, METHIMAZOLE DERIVATIVES, AND TAUTOMERIC CYCLIC THIONES FOR THE TREATMENT OF AUTOIMMUNE/INFLAMMATORY DISEASES ASSOCIATED WITH TOLL-LIKE RECEPTOR OVEREXPRESSION | UNIV OHIO (US) | 2016-08-04 | — | — | US | disclosed |
| US-9326972-B2 | Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression | OHIO UNIVERSITY (US) | 2016-05-03 | — | — | US | disclosed |
| WO-2006023710-A2 | COSMETIC OR PHARMACEUTICAL COMPOSITION FOR SKIN CARE | INFINITY2 HEALTH SCIENCES, INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| US-20060039887-A1 | Cosmetic or pharmaceutical composition for skin care | INFINITY2 HEALTH SCIENCES, INC. | 2006-02-23 | — | — | US | disclosed |
| WO-2005123101-A1 | BLACKBERRY EXTRACT | SYMRISE GMBH & CO. KG (DE) | 2005-12-29 | — | — | WO | disclosed |
| US-20050037038-A1 | Cosmetic Dermabrasion Treatment System | GUPTA SHYAM K (US) | 2005-02-17 | — | — | US | disclosed |
| US-20040228884-A1 | Ion-pair delivery system for cosmetic and pharmaceutical compositions | GUPTA SHYAM K (US) | 2004-11-18 | — | — | US | disclosed |
| US-20040166069-A1 | Boosting Tyrosinase Inhibiting Activity of Skin Whitening and Sunscreen Compositions | GUPTA SHYAM K (US) | 2004-08-26 | — | — | US | disclosed |
| US-20040092482-A1 | Hydroxy acids based delivery systems for skin resurfacing and anti-aging compositions | GUPTA SHYAM K (US) | 2004-05-13 | — | — | US | disclosed |
| US-20040081672-A1 | Niacinamide, niacin, and niacin esters based delivery systems for treating topical disorders of skin and skin aging | GUPTA SHYAM K (US) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092482-A1 | Hydroxy acids based delivery systems for skin resurfacing and anti-aging compositions | CUTA, HIRA, HARS1 | F7 3378/4885F3 4156/4885SARM1 4221/4885 |
| US-20180177703-A1 | Niacinamide Mononucleotide Formulations For Skin Aging | NAMPT, NNT, NAPRT | F7 2895/4885F3 2373/4885SARM1 23/4885 |
| US-20160220536-A1 | USE OF PHENYLMETHIMAZOLES, METHIMAZOLE DERIVATIVES, AND TAUTOMERIC CYCLIC THIONES FOR THE TREATMENT OF AUTOIMMUNE/INFLAMMATORY DISEASES ASSOCIATED WITH TOLL-LIKE RECEPTOR OVEREXPRESSION | IRF3, TLR3, TLR4 | F7 3797/4885F3 671/4885SARM1 3530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.